Astellas bolsters oncology arsenal with $1.4 billion tivozanib deal
This article was originally published in Scrip
Executive Summary
Astellas has taken another decisive step into oncology with a deal covering the ex-Asia global rights to AVEO Pharmaceuticals' lead product tivozanib that could eventually be worth around $1.4 billion to the US firm.